Genezen to Acquire Massachusetts Gene Therapy Manufacturing Operations from uniQure https://ow.ly/1Xje50SxieB
BioPharm International
Book and Periodical Publishing
Iselin, NJ 1,729 followers
Talking biopharmaceuticals, biotechnology, bioprocessing and related pharma manufacturing.
About us
BioPharm International integrates the science and business of biopharmaceutical development, and manufacturing. We provide practical, peer-reviewed technical articles to enable biopharmaceutical professionals to perform their jobs more effectively. We believe that technical decisions are also business decisions and give readers the tools to make both sound business and technical decisions.
- Website
-
http://www.biopharminternational.com
External link for BioPharm International
- Industry
- Book and Periodical Publishing
- Company size
- 501-1,000 employees
- Headquarters
- Iselin, NJ
- Type
- Privately Held
Locations
-
Primary
Get directions
485F US Hwy 1 South, Ste. 210
Iselin, NJ 08830-3009, US
Updates
-
Genezen to Acquire Massachusetts Gene Therapy Manufacturing Operations from uniQure https://ow.ly/1Xje50SxieB
Genezen to Acquire Massachusetts Gene Therapy Manufacturing Operations from uniQure
biopharminternational.com
-
#ICYMI Check out this story on BioPharm International on how #NorthAmerica gains broader access to cell-free protein synthesis technology, courtesy of a strategic partnership between LenioBio and Labscoop! https://ow.ly/jxNQ50SuZ3h #biopharma #protein #synthesistechnology #cellfree
LenioBio and Labscoop’s Strategic Partnership Aimed at Enhancing Access to Cell-Free Protein Synthesis
biopharminternational.com
-
EMA gave positive opinions on a nasal delivery for epinephrine and for a first-in-class medicine to treat pulmonary arterial hypertension. https://ow.ly/AY1550SuTYg
First Nasal Adrenaline Spray Among EMA Approvals in June
biopharminternational.com
-
#NorthAmerica to gain broad access to cell-free protein synthesis technology under a new partnership between LenioBio and Labscoop If you missed the story, check it out now on BioPharm International! https://ow.ly/jxNQ50SuZ3h #biopharma #protein #synthesistechnology #cellfree
LenioBio and Labscoop’s Strategic Partnership Aimed at Enhancing Access to Cell-Free Protein Synthesis
biopharminternational.com
-
EMA gave positive opinions on a nasal delivery for epinephrine and for a first-in-class medicine to treat pulmonary arterial hypertension. https://ow.ly/AY1550SuTYg
First Nasal Adrenaline Spray Among EMA Approvals in June
biopharminternational.com
-
Cell-free protein synthesis technology gets broader access with a new partnership between LenioBio and Labscoop Check out the story on BioPharm International! https://ow.ly/jxNQ50SuZ3h #biopharma #protein #synthesistechnology #cellfree
LenioBio and Labscoop’s Strategic Partnership Aimed at Enhancing Access to Cell-Free Protein Synthesis
biopharminternational.com
-
In the premiere episode of the Ask the Expert video series, Susan Schniepp, distinguished fellow at Regulatory Compliance Associates (RCA), and Siegfried Schmitt, vice president, Technical at Parexel, discuss the challenges involved in changing an excipient supplier. https://ow.ly/HsNO50Srfky
Quality Considerations in Changing Excipient Providers
biopharminternational.com
-
In the premiere episode of the Ask the Expert video series, Susan J. Schneipp, distinguished fellow at Regulatory Compliance Associates, and Siegfried Schmitt, vice president, Technical at Parexel, discuss the challenges involved in changing an excipient supplier. https://ow.ly/HsNO50Srfky
Quality Considerations in Changing Excipient Providers
biopharminternational.com
-
Yoni Tyberg, associate director of the Special Program Staff in the Office of New Drugs, provided an update on efforts to modernize CDER processes. https://lnkd.in/gUtJBWk7
FDA Provides Update on New Drugs Regulatory Program
biopharminternational.com